Avalo Therapeutics (AVTX) CSO granted 34,200 performance stock units vesting in 2028

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. Chief Strategy Officer Jennifer Riley reported an acquisition of 34,200 shares of Common Stock on May 21, 2026, at a stated price of $0.00 per share. After this award, she directly holds 36,855 shares.

According to the footnote, this represents performance stock units granted on August 19, 2025. Each unit is a contingent right to one share, tied to performance goals that the Compensation Committee certified on May 21, 2026. The shares are scheduled to fully vest on August 19, 2028, assuming her continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Riley Jennifer

Role Chief Strategy Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	34,200	$0.00	--

Holdings After Transaction: Common Stock — 36,855 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 34,200 shares Post-transaction holdings: 36,855 shares Award price: $0.00 per share +2 more

5 metrics

Shares acquired 34,200 shares Grant/award of Common Stock on May 21, 2026

Post-transaction holdings 36,855 shares Common Stock directly owned after award

Award price $0.00 per share Stated transaction price for the grant

PSU grant date August 19, 2025 Date PSUs were originally granted

PSU vesting date August 19, 2028 Scheduled full vesting date, subject to continued service

Key Terms

performance stock units, contingent right, Compensation Committee, vesting

4 terms

performance stock units financial

"Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025."

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

contingent right financial

"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock"

Compensation Committee financial

"On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals."

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

vesting financial

"the shares subject to the PSUs shall fully vest on August 19, 2028"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Riley Jennifer

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Strategy Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		A(1)		34,200	A	$0	36,855	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Avalo Therapeutics (AVTX) disclose in Jennifer Riley’s latest Form 4?

Avalo Therapeutics (AVTX) disclosed that Chief Strategy Officer Jennifer Riley acquired 34,200 shares of Common Stock via a performance-based equity award. The transaction was reported at a price of $0.00 per share, bringing her direct holdings to 36,855 shares after the award.

How many Avalo Therapeutics (AVTX) shares does Jennifer Riley hold after this transaction?

After the reported award, Jennifer Riley directly holds 36,855 shares of Avalo Therapeutics Common Stock. This reflects the addition of 34,200 shares tied to performance stock units, as disclosed in the Form 4 insider transaction filing.

What type of equity award did Jennifer Riley receive from Avalo Therapeutics (AVTX)?

Jennifer Riley received performance stock units (PSUs), each representing a contingent right to one share of Avalo Therapeutics Common Stock. These PSUs depend on achieving specified performance goals and constitute a grant, award, or other acquisition rather than an open-market stock purchase.

When will Jennifer Riley’s performance stock units in Avalo Therapeutics (AVTX) vest?

The shares subject to Jennifer Riley’s performance stock units are scheduled to fully vest on August 19, 2028. Vesting is contingent on her continued service with Avalo Therapeutics through that date, following certification that required performance goals were achieved.

What performance condition was met for Jennifer Riley’s Avalo Therapeutics (AVTX) PSUs?

Avalo Therapeutics’ Compensation Committee certified achievement of the PSUs’ performance goals on May 21, 2026. This certification triggered the right for the related shares to vest on August 19, 2028, subject to Jennifer Riley’s continued service with the company.